MIM
LXEO icon

MetLife Investment Management’s Lexeo Therapeutics LXEO Stock Holding History

MetLife Investment Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Sell
35,584
-137
-0.4% -$971 ﹤0.01% 2218
2025
Q4 		$355K Buy
+35,721
New +$326K ﹤0.01% 1958
2025
Q1 		– Sell
-14,223
Closed -$93.6K – 2808
2024
Q4 		$93.6K Hold
14,223
– – ﹤0.01% 2651
2024
Q3 		$129K Buy
14,223
+7,803
+122% +$93.1K ﹤0.01% 2526
2024
Q2 		$103K Buy
6,420
+599
+10% +$8.7K ﹤0.01% 2591
2024
Q1 		$91.3K Buy
+5,821
New +$91K ﹤0.01% 2578

Other funds holding LXEO

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's LXEO Position: Q1 2026 in Review

MetLife Investment Management reduced its Lexeo Therapeutics (LXEO) stake by 0.38% in Q1 2026, selling an estimated $971 and leaving 35,584 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #2218.

MetLife Investment Management first reported a position in LXEO in Q1 2024 and has held it in 6 quarters since. The position peaked at $355K in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

  • MetLife Investment Management held 35,584 shares of Lexeo Therapeutics worth $204K as of Q1 2026.
  • MetLife Investment Management sold 137 Lexeo Therapeutics shares in Q1 2026, an estimated $971.
  • Lexeo Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2218 holding.
  • MetLife Investment Management first reported a position in Lexeo Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • MetLife Investment Management's Lexeo Therapeutics position peaked at $355K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.